Dare Bioscience

DARE · NASDAQ

$0.689+$0.0207 (+3.10%)TodayMarket closed · Oct 21, 4:04 AM ET

Prev close $0.6683

DARE analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $8.50 (+1133.7% upside)

Low: $5.05
Now: $0.689
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

DARE analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Dec 2, 2025	Maintains	Buy	$12.00	50%

The case for and against

Updated May 8, 2025

Bull case

Dare Bioscience Inc. has demonstrated noteworthy financial progress, highlighted by a significant reduction in operating loss, decreasing from $8.4 million to $4.7 million in the third quarter of 2023, which surpassed expectations. The company has secured substantial funding, including a $10.7 million grant for the development of a novel non-hormonal contraceptive and expansion of its Ovaprene pivotal study, signaling strong investor confidence and support for its initiatives. Furthermore, the probability of success for its pipeline products, particularly Ovaprene at 60%, suggests promising advancement within their clinical development, positioning Dare well within the competitive landscape of women's health.

Bear case

Dare Bioscience Inc. reported a diluted loss per share of $0.55 for the latest quarter, which was below both the analyst estimate and the broader market consensus, highlighting ongoing financial challenges. A significant decrease in R&D expenses, down 60.2% year-over-year to $2.7 million, raises concerns about the company's commitment to product development, especially regarding its key candidates, Sildenafil Cream and Ovaprene. Additionally, third-quarter revenue was disappointing, coming in below estimates at $1 million compared to the $3.1 million forecast, further indicating potential difficulties in revenue generation and growth prospects for the company in the near term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.